

Prothrombin Complex Concentrate for Major Bleeding Prospective Cohort Study

Thrombosis and Haemostasis

118, 842-851

DOI: 10.1055/s-0038-1636541

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 486-495.	2.1	19
2	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. <i>International Journal of Emergency Medicine</i> , 2018, 11, 55.	1.6	25
3	American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. <i>Blood Advances</i> , 2018, 2, 3257-3291.	5.2	328
4	Reversing anti- factor Xa agents and the unmet needs in trauma patients. <i>Blood</i> , 2018, 132, 2441-2445.	1.4	10
5	The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 117S-126S.	1.7	11
6	Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. <i>Anesthesiology</i> , 2018, 129, 1171-1184.	2.5	27
7	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 499-506.	3.8	6
8	The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban. <i>Chest</i> , 2019, 155, 1309-1311.	0.8	0
9	Response. <i>Chest</i> , 2019, 155, 1309.	0.8	1
10	Just the facts: Management of life-threatening bleeding with oral anticoagulant use in the emergency department. <i>Canadian Journal of Emergency Medicine</i> , 2019, 21, 460-463.	1.1	1
11	Throwing it in reverse: An update on reversal of oral factor Xa inhibitors. <i>American Journal of Emergency Medicine</i> , 2019, 37, 1978-1980.	1.6	7
12	Andexanet alfa for the reversal of factor Xa inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 387-397.	3.1	10
13	Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 250-255.	2.1	71
14	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	27.0	687
15	Haematological management of major bleeding associated with direct oral anticoagulants – UK experience. <i>British Journal of Haematology</i> , 2019, 185, 514-522.	2.5	15
16	Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 204-208.	2.5	3
17	Andexanet Response. <i>Annals of Emergency Medicine</i> , 2019, 74, 724-725.	0.6	0
18	Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. <i>Blood Advances</i> , 2019, 3, 158-167.	5.2	92

#	ARTICLE	IF	CITATIONS
19	Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. Future Cardiology, 2019, 15, 395-404.	1.2	5
20	Andexanet Alfa: Considerations and Practical Applications. Critical Pathways in Cardiology, 2019, 18, 200-206.	0.5	1
21	Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. Hematologie, 2019, 25, 233-247.	0.0	0
22	Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. Anesthesiology, 2019, 131, 1153-1165.	2.5	14
23	Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. Annales De Biologie Clinique, 2019, 77, 67-78.	0.1	1
24	FDA Approval of Andexanet Alfa Based on a Single-Arm Trial: If There Is a Villain, Who Is It?. Annals of Emergency Medicine, 2019, 74, 725-727.	0.6	0
25	Treatment of bleeding complications in patients on anticoagulant therapy. Blood, 2019, 133, 425-435.	1.4	65
26	Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace, 2019, 21, 414-420.	1.7	31
27	Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients. Journal of Intensive Care Medicine, 2020, 35, 903-908.	2.8	35
28	A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. Trends in Cardiovascular Medicine, 2020, 30, 86-90.	4.9	37
29	A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage. Journal of Intensive Care Medicine, 2020, 35, 1203-1208.	2.8	31
30	Direct oral anticoagulant (DOAC) reversal: Andexxa versus 4 factor prothrombin concentrates. Transfusion and Apheresis Science, 2020, 59, 102649.	1.0	2
31	Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Genetics in Medicine, 2020, 22, 160-169.	2.4	41
32	Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. Journal of Thrombosis and Thrombolysis, 2020, 49, 121-131.	2.1	60
33	Non-activated prothrombin complex concentrates for major bleeding in patients on apixaban and rivaroxaban. Internal and Emergency Medicine, 2020, 15, 1123-1124.	2.0	4
34	Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocritical Care, 2020, 33, 20-24.	2.4	15
35	Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding. American Journal of Cardiovascular Drugs, 2020, 20, 295-299.	2.2	11
36	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Annals of Emergency Medicine, 2020, 76, 470-485.	0.6	46

#	ARTICLE	IF	CITATIONS
37	Real-world utilization of andexanet alfa. American Journal of Emergency Medicine, 2020, 38, 810-814.	1.6	28
38	Does a dose relationship exist with prothrombin complex and factor Xa inhibitor reversal? An alternate perspective of Yohe et al.. American Journal of Emergency Medicine, 2020, 38, 686-687.	1.6	0
39	Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate. American Journal of Emergency Medicine, 2020, 38, 2641-2645.	1.6	11
40	Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. Thrombosis Research, 2020, 196, 404-409.	1.7	0
41	Treatment of intracerebral hemorrhage: From specific interventions to bundles of care. International Journal of Stroke, 2020, 15, 945-953.	5.9	15
42	Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal. Thrombosis Research, 2020, 194, 158-164.	1.7	17
43	An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. Clinical Neurology and Neurosurgery, 2020, 195, 106070.	1.4	17
44	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2020, 76, 594-622.	2.8	187
45	Prothrombin complex concentrates for DOAC-associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact?. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 677-679.	2.3	4
46	Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa. Journal of Thrombosis and Haemostasis, 2020, 18, 2532-2541.	3.8	20
47	Reply to "Key Points to Consider When Evaluating Andexxa for Formulary Addition". Neurocritical Care, 2020, 33, 323-326.	2.4	1
48	Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1282-1294.	2.3	19
49	Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies. Seminars in Thrombosis and Hemostasis, 2020, 46, 986-998.	2.7	7
50	Anticoagulation Management in Geriatric Orthopedic Trauma Patients. Current Geriatrics Reports, 2020, 9, 288-295.	1.1	2
51	Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review. BMJ Open, 2020, 10, e040499.	1.9	7
52	A review of guidelines on anticoagulation reversal across different clinical scenarios "Is there a general consensus?". American Journal of Emergency Medicine, 2020, 38, 1890-1903.	1.6	26
53	How Do I Reverse Oral and Parenteral Anticoagulants?. Hamostaseologie, 2020, 40, 201-213.	1.9	5
54	Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal. World Neurosurgery, 2020, 142, e95-e100.	1.3	4

#	ARTICLE	IF	CITATIONS
55	Thrombin generation and bleeding in cardiac surgery: a clinical narrative review. Canadian Journal of Anaesthesia, 2020, 67, 746-753.	1.6	11
56	Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes. Thrombosis Research, 2020, 195, 21-28.	1.7	8
57	Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series. Journal of Pharmacy Practice, 2020, 34, 089719002090701.	1.0	12
58	Request for an Andexxa Value Analysis. Annals of Pharmacotherapy, 2020, 54, 715-717.	1.9	3
59	Age-adjusted D-dimer cutoff for the diagnosis of pulmonary embolism: A cost-effectiveness analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 865-875.	3.8	18
60	Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 569-581.	2.3	18
61	Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. Journal of Thrombosis and Haemostasis, 2020, 18, 1637-1647.	3.8	70
62	An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants. Advances in Hematology, 2020, 2020, 1-10.	1.0	24
63	Factor Xa Inhibitor-Related Intracranial Hemorrhage. Circulation, 2020, 141, 1681-1689.	1.6	66
64	Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study. Journal of Intensive Care Medicine, 2021, 36, 597-603.	2.8	13
65	Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products. Journal of Thrombosis and Thrombolysis, 2021, 51, 151-158.	2.1	23
66	Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. Future Cardiology, 2021, 17, 127-135.	1.2	24
67	Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review. Pharmacotherapy, 2021, 41, 28-43.	2.6	15
68	Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery, 2021, 61, 9-82.	1.5	308
69	Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery. , 2021, , 71-91.		0
70	Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors – An In Vitro Study. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110211.	1.7	2
71	Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines. Digestive Diseases and Sciences, 2021, 66, 3698-3714.	2.3	8
72	Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110390.	1.7	14

#	ARTICLE	IF	CITATIONS
73	Reversal of direct oral anticoagulants: Highlights from the Anticoagulation Forum guideline. Cleveland Clinic Journal of Medicine, 2021, 88, 98-103.	1.3	2
74	Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. Western Journal of Emergency Medicine, 2021, 22, 163-169.	1.1	4
75	Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors. Journal of Thrombosis and Thrombolysis, 2021, 52, 828-835.	2.1	6
76	Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 1112-1115.	3.8	8
77	Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage. Annals of Pharmacotherapy, 2021, 55, 1455-1466.	1.9	3
78	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	1.7	494
79	Review of Prothrombin Complex Concentrates Use in Apixaban and Rivaroxaban Associated Intracranial Hemorrhages. Journal of Pharmacy Practice, 2021, , 089719002110150.	1.0	0
80	Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2021, 52, 1137-1150.	2.1	5
81	A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12518.	2.3	11
82	Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology, 2021, 18, 649-665.	13.7	49
83	Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis. Critical Care Medicine, 2021, 49, e1025-e1036.	0.9	33
84	Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. Journal of the American College of Cardiology, 2021, 77, 2987-3001.	2.8	69
85	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke, 2021, 52, 2096-2105.	2.0	25
86	Direct oral anticoagulant reversal: An update. Nursing, 2021, 51, 54-64.	0.3	2
87	Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. Journal of Thrombosis and Thrombolysis, 2022, 53, 167-175.	2.1	20
88	Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center. Journal of Thrombosis and Thrombolysis, 2022, 53, 158-166.	2.1	6
89	Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review. Brazilian Journal of Anesthesiology (Elsevier), 2021, 71, 429-442.	0.4	2
90	A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings. Journal of Pharmacy Practice, 2023, 36, 221-226.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. European Journal of Preventive Cardiology, 2022, 29, 1248-1263.	1.8	40
92	Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	3
93	Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal Model. Anesthesiology, 2021, 135, 673-685.	2.5	9
94	Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2022, 20, 103-113.	1.0	9
95	Coagulation Management after Trauma in the Presence of Direct Oral Anticoagulants. Anesthesiology, 2021, 135, 570-572.	2.5	3
96	Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. European Heart Journal, 2022, 43, 985-992.	2.2	25
97	Prehospital and Emergency Department Care of the Patient With Acute Stroke. , 2022, , 735-749.e3.		0
98	The Year in Coagulation: Selected Highlights From 2019. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1745-1754.	1.3	7
99	Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. Anesthesiology, 2020, 133, 223-232.	2.5	2
100	What we have learned about direct oral anticoagulant reversal. Hematology American Society of Hematology Education Program, 2019, 2019, 198-203.	2.5	11
101	Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events. Thrombosis Update, 2021, 5, 100076.	0.9	1
102	Prise en charge h�modynamique des h�morrhagies c�r�brales sous anticoagulants oraux. Medecine Intensive Reanimation, 2019, 28, 363-370.	0.0	0
103	Management of Chronically Anticoagulated Patients. , 2021, , 663-676.		0
104	Direct oral anticoagulant reversal. Nurs Crit Care (Ambler), 2020, 15, 18-29.	0.2	1
105	Early anticoagulant reversal after trauma: A Western Trauma Association critical decisions algorithm. Journal of Trauma and Acute Care Surgery, 2021, 90, 331-336.	2.1	7
106	Use of direct oral anticoagulants in ICU patients. Part I �� Applied pharmacology. Anaesthesiology Intensive Therapy, 2021, 53, 429-439.	1.0	3
107	Reversal of anticoagulation in neurosurgical and neurocritical care settings. , 2022, , 239-266.		0
108	Emergency cardiac surgery in patients on oral anticoagulants and antiplatelet medications. Journal of Cardiac Surgery, 2022, 37, 214-222.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 74-81.	2.1	4
110	Prothrombin complex concentrates for the urgent reversal of apixaban and rivaroxaban – an Australian retrospective cohort study. <i>Internal Medicine Journal</i> , 2021, , .	0.8	0
111	Use of direct oral anticoagulants in ICU patients. Part II – Clinical evidence. <i>Anaesthesiology Intensive Therapy</i> , 2021, 53, 440-449.	1.0	4
112	Regional anaesthesia in patients on antithrombotic drugs. <i>European Journal of Anaesthesiology</i> , 2022, 39, 100-132.	1.7	82
113	Decision-Making Process for the Management of Acute Stroke in Patients on Oral Anticoagulant: From Guidelines to Clinical Routine. <i>Frontiers in Neurology</i> , 2021, 12, 794001.	2.4	1
114	Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1323-1329.	1.0	7
115	Recommendations from the ICM-VTE: General. <i>Journal of Bone and Joint Surgery - Series A</i> , 2022, 104, 4-162.	3.0	14
116	Cost-effectiveness of andexanet-Åalfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US. <i>Journal of Medical Economics</i> , 2022, 25, 309-320.	2.1	6
117	Use of Prothrombin Complex Concentrate in Oral Anticoagulant-Associated Major Bleeding. <i>Critical Care Nursing Quarterly</i> , 2022, 45, 167-179.	0.8	0
118	Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. <i>American Journal of Emergency Medicine</i> , 2022, 55, 38-44.	1.6	15
119	Management of Coagulopathy in Bleeding Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1.	2.4	24
120	Anticoagulants: dose control methods and inhibitors. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 16, 158-175.	0.5	2
123	Perioperative Management of Direct Oral Anticoagulants in Cardiac Surgery: Practice Recommendations Based on Current Evidence. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 4141-4149.	1.3	1
124	Emergent Reversal of Antithrombotics and Treatment of Life-Threatening Bleeding from Coagulopathies: A Clinical Review. <i>Journal of Emergency Medicine</i> , 2022, 63, 17-48.	0.7	3
125	A Historical Perspective on the Reversal of Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	2.7	3
126	A short review of ciraparantag in perspective of the currently available anticoagulant reversal agents. <i>Drug Discovery Today</i> , 2022, 27, 103332.	6.4	2
127	Prothrombin Complex Concentrate in Emergency Department. <i>Acta Clinica Croatica, Supplement</i> , 2022, , .	0.2	0
128	Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery. <i>Journal of Pharmacy Practice</i> , 2024, 37, 74-79.	1.0	2

#	ARTICLE	IF	CITATIONS
129	Direct Oral Anticoagulant Reversal in the Pediatric Emergency Department. <i>Pediatric Emergency Care</i> , 2022, 38, 621-625.	0.9	0
130	Contemporary Perioperative Management of Direct Oral Anticoagulants. <i>Advances in Anesthesia</i> , 2022, 40, 93-109.	0.9	0
131	The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage. <i>American Journal of Emergency Medicine</i> , 2023, 64, 74-77.	1.6	2
132	Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 55, 519-526.	2.1	4
133	Prothrombin Complex Concentrate should be Used to Reverse Factor Xa Inhibitors in the Setting of Life-Threatening Bleeding. <i>Annals of Emergency Medicine</i> , 2023, , .	0.6	1
134	DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 433-452.	3.8	7
135	Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. <i>Circulation</i> , 2023, 147, 1026-1038.	1.6	24
136	Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding. <i>European Heart Journal</i> , 2023, 44, 1780-1794.	2.2	3
137	Evaluation and management of oral anticoagulant bleeding: quid didicimus? (what have we learned?). <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 460-462.	3.8	1
138	Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100107.	2.3	2
139	HÄmostase. <i>Springer Reference Medizin</i> , 2023, , 1-34.	0.0	0
140	Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 137-146.	2.1	4
141	Massive Apixaban Overdose Confirmed with Blood Concentrations and Managed Without Bleeding: A Single Case Report. <i>Journal of Pharmacy Practice</i> , 0, , 089719002311775.	1.0	2
142	Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962311796.	1.7	0
143	Direct oral anticoagulants and their antagonists in perioperative practice. <i>Current Opinion in Anaesthesiology</i> , 2023, 36, 394-398.	2.0	2
144	Atrial Fibrillation in Kidney Failure: Challenges in Risk Assessment and Anticoagulation Management. <i>Kidney Medicine</i> , 2023, 5, 100690.	2.0	0
145	Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors. <i>Thrombosis Research</i> , 2023, 229, 46-52.	1.7	0
146	Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants. <i>Annals of Emergency Medicine</i> , 2023, 82, 341-361.	0.6	1

#	ARTICLE	IF	CITATIONS
147	The Hard Bargain of Anticoagulation after Intracranial Hemorrhage, in the Setting of Venous Thromboembolism: Between a Rock and a Hard Place. <i>Thrombosis and Haemostasis</i> , 2023, 123, 976-977.	3.4	1
148	Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale. <i>TH Open</i> , 2023, 07, e229-e240.	1.4	0
149	Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland. <i>Swiss Medical Weekly</i> , 2023, 153, 40113.	1.6	2
150	Evidence-based Management of Major Bleeding in Patients Receiving Direct Oral Anticoagulants: An Updated Narrative Review on the Role of Specific Reversal Agents. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2023, 28, .	2.0	0
151	Four-factor prothrombin complex concentrate versus andexanet Alfa for direct oral anticoagulant reversal. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2023, , .	1.5	0
152	Regional anesthesia and anticoagulation: a narrative review of current considerations. <i>International Anesthesiology Clinics</i> , 2024, 62, 1-9.	0.8	0
153	Efficacy and Safety of Activated Prothrombin Complex Concentrate for Reversal of the Anticoagulant Effect of Apixaban and Rivaroxaban in Patients with Major Bleeding. <i>Clinical Drug Investigation</i> , 2023, 43, 883-888.	2.2	1
154	Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma. <i>Current Opinion in Anaesthesiology</i> , 2024, 37, 101-109.	2.0	0
155	Management of patients with proximal femur fractures under DOACs. <i>European Journal of Trauma and Emergency Surgery</i> , 2024, 50, 359-366.	1.7	0
156	Recognize, reverse, resume, reduce: A framework for managing severe DOAC-related bleeding. <i>Thrombosis Update</i> , 2024, , 100165.	0.9	0
157	Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2024, 30, .	1.7	0